The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

NCT04277663 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

136

Enrollment

INDUSTRY

Sponsor class

Stopped Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue the study after consultation with investigators

Conditions

Acral Melanoma That Has Been Removed by Surgery

Interventions

DRUG: IBI310+IBI308
DRUG: IBI308
DRUG: High-dose recombinant interferon a-2B

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.